Weed is Actually ‘Rarely Justified’ to Treat Anxiety or Depression, Says Major Scientific Review
#78 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need this evidence summary to counter patient requests for cannabis as an anxiety or depression treatment, since the review found insufficient evidence supporting efficacy while noting potential harms. Understanding that cannabis may worsen rather than improve psychiatric symptoms allows providers to redirect patients toward evidence-based interventions like psychotherapy and FDA-approved medications. This guidance protects vulnerable populations who might self-medicate with cannabis instead of seeking proven mental health treatments.
A comprehensive scientific review examining cannabis use for anxiety and depression found insufficient evidence to support its routine clinical application for these common mental health conditions. While some patients report subjective symptom relief, the authors noted that available evidence is limited by small sample sizes, short study durations, and lack of rigorous randomized controlled trials comparing cannabis to established psychiatric treatments. The review highlighted particular concern that cannabis may paradoxically worsen anxiety or depression in some patients and carries risks of dependence and cognitive effects, especially with regular use. Current evidence suggests that cannabis treatment for mood and anxiety disorders is “rarely justified” compared to first-line pharmacological and psychotherapeutic interventions with robust efficacy data. Clinicians should exercise caution when patients request cannabis for depression or anxiety, as doing so may delay evidence-based treatment and expose patients to unnecessary adverse effects. Patients seeking mental health treatment should discuss cannabis use with their providers and understand that conventional therapies like antidepressants and cognitive behavioral therapy remain the standard of care with superior evidence bases for anxiety and depression.
“After two decades of clinical practice, I can tell you that the evidence simply doesn’t support cannabis as a first-line treatment for anxiety or depression, and patients deserve to hear that clearly rather than self-medicating based on anecdote or hope. What we’re seeing in practice is that while some patients report subjective relief, the risk of dependence, cognitive effects, and symptom worsening in vulnerable populations outweighs the benefit for most people struggling with mood disorders.”
? While cannabis is increasingly sought by patients for anxiety and depression, a major scientific review finding insufficient evidence for mental health benefit should prompt clinicians to reconsider recommending it as a first-line option. The heterogeneity of cannabis products (varying cannabinoid ratios, delivery methods, and dosing), limited high-quality randomized controlled trials, and potential for symptom exacerbation in vulnerable populations complicate the evidence base significantly. Additionally, the retrospective nature of much existing data and publication bias toward positive findings likely overestimate true efficacy, and concurrent use with other psychotropic medications introduces potential drug interactions that are poorly characterized. Clinicians should continue to prioritize evidence-based treatments such as psychotherapy and selective serotonin reuptake inhibitors as first-line interventions, while discussing with patients that cannabis for mood or anxiety remains largely unproven and may carry individual risks including dependence, cognitive effects,
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it:
